News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

KaloBios Pharmaceuticals, Inc. Initiates Phase 2 Study With KB003 Humaneered™ Monoclonal Antibody in Severe Asthma


9/12/2012 10:31:59 AM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company’s anti-GM-CSF Humaneered™ monoclonal antibody, in subjects with severe asthma uncontrolled by corticosteroids.

Read at BioSpace.com


comments powered by Disqus
   
Asthma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES